TITLE

Prostate cancer screening: waiting for Godot

AUTHOR(S)
Iscoe, Neill A.; Iscoe, N A
PUB. DATE
December 1998
SOURCE
CMAJ: Canadian Medical Association Journal;12/01/98, Vol. 159 Issue 11, p1375
SOURCE TYPE
Academic Journal
DOC. TYPE
editorial
ABSTRACT
Editorial. Discusses a study by Maurice McGregor on prostate cancer screening in this issue and whether screening does more good than harm. Why controversy exists over this issue; The aspect over overdetection in breast cancer; The three classes of prostate cancer.
ACCESSION #
1330390

 

Related Articles

  • Screening.  // Journal of Health Services Research & Policy;Jan2017, Vol. 22 Issue 1, p45 

    The article focuses on findings of a study on implementation of an evidence-based policy for prostate cancer screening in Great Britain, and mentions that prostate cancers can be diagnosed when potentially curable following screening with a prostate specific antigen (PSA) blood test.

  • Annual screening beneficial for high-risk PCa.  // Urology Times;Dec2012, Vol. 40 Issue 13, p5 

    The article offers information on the result of a study which unveils the beneficial effects of annual prostate specific antigen (PSA) screening in providing greater quality-adjusted life expectancy among patients who have high risk of developing metastatic diseases.

  • Screening for prostate cancer in younger men. Illic, Dragen; Green, Sally // BMJ: British Medical Journal (International Edition);12/1/2007, Vol. 335 Issue 7630, p1105 

    The authors reflect upon screening for prostate cancer in younger men across the globe. They suggest that randomised controlled trials have led to uncertain results about the effectiveness of the cancer testing, its effect on quality of life and its potential harms and costs. They argue that...

  • Study: Monitor subgroup of young, high-risk men. Kuznar, Wayne // Urology Times;Jan2012, Vol. 40 Issue 1, p14 

    The article reports that result of the case-control study conducted by American and Swedish researchers showed that men with 10% PSA levels at the age of 44 to 50 years have a higher risks of prostate cancer death. Doctor Hans G. Lilja said that the results of the study identify a subgroup of...

  • Task Force won't bend on PSA screening; urologists respond.  // Urology Times;Jun2012, Vol. 40 Issue 7, p5 

    The article reports on the decision of the U.S. Preventive Services Task Force (USPSTF) of not altering its grade D recommendation on prostate-specific antigen (PSA)-based screening. According to Sushil I. Lacy, president of the American Urological Association (AUA), the AUA is offended at the...

  • Excess all-cause mortality in the evaluation of a screening trial to account for selective participation. Kranse, Ries; van Leeuwen, Pim J; Hakulinen, Timo; Hugosson, Jonas; Tammela, Teuvo L; Ciatto, Stefano; Roobol, Monique J; Zappa, Marco; Aus, Gunar; Bangma, Chris H; Moss, Sue M; Auvinen, Anssi; Schröder, Fritz H // Journal of Medical Screening;Mar2013, Vol. 20 Issue 1, p39 

    The article presents a study that examines the effectiveness of mortality evaluation on patients with prostate cancer. It describes the method of the study that uses estimation procedure in the expected number of deaths related to prostate cancer diagnoses. It outlines the findings of the study...

  • MRI Can Accurately Detect Significant Prostate Cancer.  // Renal & Urology News;Sep2014, Vol. 13 Issue 9, p21 

    The article presents a study conducted by researcher Lauren J. Bains and her colleagues at the University of Bern in Switzerland about the importance of diffusion-weighted magnetic resonance imaging (DW-MRI) in detecting significant prostate tumors.

  • Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials. Djulbegovic, Mia; Beyth, Rebecca J.; Neuberger, Molly M.; Stoffs, Taryn L.; Vieweg, Johannes; Djulbegovic, Benjamin; Dahm, Philipp // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;9/18/2010, Vol. 341 Issue 7773, p593 

    The article offers information on a study which investigated the benefits and disadvantages of screening for prostate cancer. Electronic databases analyzed in the study included Medline, Embase and CENTRAL, as well as abstract proceedings and reference lists through July 13, 2010 without...

  • 153-14. PSA VALUE.  // Cortlandt Forum;11/25/2000, Vol. 13 Issue 11, p88 

    Cites advantages of prostate-specific antigen (PSA) screening. Ability of the PSA screening to detect stage 1 cancer; Concerns over PSA screening.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics